https://scholars.lib.ntu.edu.tw/handle/123456789/578076
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Liou B.-H. | en_US |
dc.contributor.author | HSIN-YUN SUN | en_US |
dc.contributor.author | Yang C.-J. | en_US |
dc.contributor.author | Syue L.-S. | en_US |
dc.contributor.author | Lee Y.-L. | en_US |
dc.contributor.author | Tang H.-J. | en_US |
dc.contributor.author | Tsai H.-C. | en_US |
dc.contributor.author | Lin C.-Y. | en_US |
dc.contributor.author | Chen T.-C. | en_US |
dc.contributor.author | Lee C.-Y. | en_US |
dc.contributor.author | Huang S.-H. | en_US |
dc.contributor.author | Liu C.-W. | en_US |
dc.contributor.author | Lu P.-L. | en_US |
dc.contributor.author | Lin S.-P. | en_US |
dc.contributor.author | Wang N.-C. | en_US |
dc.contributor.author | ARISTINE CHENG | en_US |
dc.contributor.author | Ko W.-C. | en_US |
dc.contributor.author | Cheng S.-H. | en_US |
dc.contributor.author | CHIEN-CHING HUNG | en_US |
dc.contributor.author | the Taiwan HIV Study Group | en_US |
dc.date.accessioned | 2021-08-16T08:36:11Z | - |
dc.date.available | 2021-08-16T08:36:11Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 2193-8229 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103069272&doi=10.1007%2fs40121-021-00424-8&partnerID=40&md5=736e4bd066b5affbd28a7e051a966945 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/578076 | - |
dc.description.abstract | Introduction: While coformulated ledipasvir (90?mg)/sofosbuvir (400?mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection. Methods: From January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12?weeks off-therapy (SVR12). Results: Of the 114 patients (mean age, 38.6?years) initiating LDV/SOF during the study period, 0.9% had liver cirrhosis and 4.4% were HCV treatment-experienced. All patients had estimated glomerular filtration rate (eGFR)?>?30?ml/min/1.73?m2 and were receiving antiretroviral therapy with 98.2% having CD4 counts???200 cells/mm3 and 93.9% plasma HIV RNA load?<?50 copies/ml. Antiretrovirals prescribed included tenofovir alafenamide/emtricitabine in 42.1%, tenofovir disoproxil fumarate (TDF)/emtricitabine 18.4%, other nucleoside reverse transcriptase inhibitors (NRTIs) 39.5%, non-NRTIs 12.3%, protease inhibitors 13.2%, and integrase inhibitors 74.6%. All patients had undetectable plasma HCV RNA load at the end of treatment, and 96.5% achieved SVR12 in intention-to-treat analysis. The on-treatment eGFR decline was more pronounced in those receiving TDF-containing antiretroviral therapy (mean change, ??8.33?ml/min/1.73?m2), which was reversible after discontinuation of LDV/SOF. None of the patients interrupted LDV/SOF during the 12-week treatment course. Conclusion: Similar to the response observed among HIV-negative patients, LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2. ? 2021, The Author(s). | - |
dc.publisher | Adis | - |
dc.relation.ispartof | Infectious Diseases and Therapy | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; amiodarone; aspartate aminotransferase; entecavir; integrase inhibitor; lamivudine; ledipasvir; phenytoin; proteinase inhibitor; sofosbuvir; acute hepatitis C; adult; antiretroviral therapy; Article; cell cycle arrest; chronic hepatitis B; chronic kidney failure; coinfection; comparative effectiveness; data analysis software; echography; estimated glomerular filtration rate; female; genotype; hemodialysis; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; Human immunodeficiency virus; liver cirrhosis; major clinical study; male; multicenter study; prevalence; retrospective study; viremia; virus load; virus replication | - |
dc.title | Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s40121-021-00424-8 | - |
dc.identifier.scopus | 2-s2.0-85103069272 | - |
dc.relation.pages | 827-838 | - |
dc.relation.journalvolume | 10 | - |
dc.relation.journalissue | 2 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Tropical Medicine and Parasitology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0003-0074-7721 | - |
crisitem.author.orcid | 0000-0002-1182-7375 | - |
crisitem.author.orcid | 0000-0001-7345-0836 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。